Canaquest Medical Corporation · OTC:CANQF
Canaquest Medical — Investor Presentation (March 2022)
15 slides from Canaquest Medical's investor presentation, March 2022
Slide 1: Corporate Presentation Q1, 2022
Corporate Presentation Q1, 2022 Mission | To advance cannabinoid & botanical-based medicine to the forefront by deploying best-practice science, clinical trials, and emerging technologies
Slide 2: Forward Looking Statements
Forward Looking Statements To the extent of statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company’s management.
Slide 3: Problem – Mental Disorders On The Rise
Problem – Mental Disorders On The Rise | Limited science behind “medical” cannabinoid products • Global cost - mental disorders will cost the global economy $16 trillion by 2030¹ • Mental health ailments - 1 in 5 North Americans has some type of mental health condition2,3 • Limited science-backed ca
Slide 4: Solution - Game Changing Formulations
Solution - Game Changing Formulations |Cannabinoid molecules used as formulation bases for Rx drug candidates CQ-001 - CBD molecules + formula Drug candidate • Molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central n
Slide 5: Value Proposition – Rx Drug Candidates for Pre-approved Trials
Value Proposition – Rx Drug Candidates for Pre-approved Trials |Novel formulation bases, proprietary processing, and delivery formats for Rx drug candidates (1) University of Montreal Hospital Research Centre Ontario Brain Institute • Pre-clinical trials completed – Western University • Pre-approved
Slide 6: The Scientific Difference
The Scientific Difference CBD vs. Rx CQ-001 Pure Cannabidiol Scientifically developed proprietary formula CBD…… • Does not effectively cross the blood-brain barrier “BBB“ to reach the section of the brain that regulates emotion. Thus, CBD alone is not effective for treating mental ailments. • Has no
Slide 7: Pharmaceutical Comparable - Unique Formulation
Pharmaceutical Comparable - Unique Formulation | Comparison with similar FDA approved product Rx CQ-001 Epidiolex® Double acting formula – on the center nervous system (the brain) Acts on the endocannabinoid system, requiring high dosage to and endocannabinoid system reach desired results at the bra
Slide 8: The Scientific Difference
The Scientific Difference THC vs Rx CQ-002 Pure Cannabinoid Scientifically developed proprietary formula THC can cause…… • Memory impairment & possible long-term cognitive side effects • Depression-like and schizophrenia-related symptoms • Anxiety and hyperactive activity • Schizophrenia due to gene
Slide 9: Mental Health Costs
Mental Health Costs | Significant Mental Health Ailments to be Addressed $16 Trillion Mental Illness Will Cost the World $16 USD Trillion by 2030¹ $225 Billion Mental Health Costs in the US reached $225 USD Billion in 2019 - 5.5% of all health spending2 $50 Billion Mental Illness in Canada is at lea
Slide 10: Pharmaceutical Regulatory Pathway To Market - Rx CQ-001
Pharmaceutical Regulatory Pathway To Market - Rx CQ-001 | Patients Suffering from Epilepsy – Dravet & Lennox Gastaut Syndrome, and Tuberous Sclerosis Complex Total Addressable Market ~ 1.1M patients worldwide Serviceable Addressable Market 160,000 patients in US, Canada & EU Serviceable Obtainable M
Slide 11: Executive Team & Board of Directors
Executive Team & Board of Directors | 100+ Years of Management & Product Development Experience Richard Rusiniak, Mechanical Engineer, CEO – Director • Over 35 years of management, design and process experience; • Co-founder and former President, CFO, and CTO of Cymat Corp (TSX: CYM) with a market v
Slide 12: Scientific Partners & Regulatory Advisors
Scientific Partners & Regulatory Advisors Dr. Steven Laviolette, B.Sc., Ph.D., a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University, Addiction Research Group Dept. of Anatomy & Cell Biology, Dept. of Psychiatry R & D Program - 14 scientists https://www.
Slide 13: Medical Advisory Board
Medical Advisory Board | Physicians, Psychiatrists & Healthcare Practitioners – being built Remi A Menes, BSc, MBA, Chairman of the CanaQuest, Advisory Committees • Extensive commercial, operations and business development experience in the biopharmaceutical, biotech, pharmaceutical, and cannabinoid
Slide 14: CanaQuest Highlights
CanaQuest Highlights | World-leading scientists in neurology, clinical trials and Rx Drug Approvals • Leader - in cannabinoid-based drug development for treating mental health neurological conditions • Clinical trial stage - strong science, pre-clinical trial results and peer-reviewed reputable publ
Slide 15: Thank you
Thank you Contact Information: Paul Ramsay, President 416.704.3040 paul@canaquest.com www.canaquest.com 15
CanaQuest Medical — Investor Presentation (March 2022) on 6ix